Zongertinib combined with T-DXd in HER2-positive metastatic gastric, gastroesophageal junction, or esophageal carcinoma (mGEAC): First results from a phase Ib/II dose-escalation trial.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: National Cancer Center Hospital East, Hospital Universitario Fundación Jiménez Díaz, IRCCS Ospedale San Raffaele, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Vall d'Hebron Hospital Universitari, Sir Run Run Shaw Hospital, Zhejiang University, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Boehringer Ingelheim (Germany), Boehringer Ingelheim (United States), Boehringer Ingelheim (Austria)
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162563728
Cites:
Cited by:
Related to: